Compounds > nepafenac
Page last updated: 2024-09-04

nepafenac and Retinal Diseases

nepafenac has been researched along with Retinal Diseases in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barash, A; Chod, RB; Drinkwater, OJ; Gentile, RC; Giovinazzo, JV; Gologorsky, D; Jansen, ME; Kaplan, RI; Lee, RH; Rosen, RB1
Bom Aggio, F; Bottós, JM; Farah, ME; Rodrigues, EB1
Bernini, M; Costagliola, C; De Ferrari, F; Morescalchi, F; Russo, A; Semeraro, F; Turano, R; Vezzoli, S1
Awh, CC; Busbee, BG; Cleary, TS; Daniel, P; Heier, JS; Stoller, GL; Waterbury, LD1

Reviews

1 review(s) available for nepafenac and Retinal Diseases

ArticleYear
Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases.
    Developments in ophthalmology, 2016, Volume: 55

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Bromobenzenes; Diclofenac; Humans; Ketorolac; Phenylacetates; Retinal Diseases

2016

Trials

3 trial(s) available for nepafenac and Retinal Diseases

ArticleYear
Pain Control after Intravitreal Injection Using Topical Nepafenac 0.3% or Pressure Patching: A Randomized, Placebo-Controlled Trial.
    Ophthalmology. Retina, 2019, Volume: 3, Issue:10

    Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Eye Pain; Female; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Male; Middle Aged; Ophthalmic Solutions; Pain Management; Pain Measurement; Phenylacetates; Prospective Studies; Retinal Diseases; Single-Blind Method; Treatment Outcome

2019
REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
    Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:6

    Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Double-Blind Method; Female; Humans; Indomethacin; Male; Ophthalmic Solutions; Phenylacetates; Prospective Studies; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body

2016
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
    Retina (Philadelphia, Pa.), 2009, Volume: 29, Issue:9

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Benzophenones; Biological Availability; Bromobenzenes; Chromatography, High Pressure Liquid; Dinoprostone; Female; Humans; Ketorolac; Male; Mass Spectrometry; Middle Aged; Ophthalmic Solutions; Phenylacetates; Retinal Diseases; Tissue Distribution; Vitrectomy; Vitreous Body

2009